ReviewCancer reports (Hoboken, N.J.)2022
The role of MiRNA-433 in malignant tumors of digestive tract as tumor suppressor.
Review in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 7 citations in OpenAlex.
- Kinesin family member 14 in digestive tract malignancies: Oncogenic mechanisms, clinical implications, and therapeutic prospects.World journal of gastrointestinal oncology · 2025Article
- Chemotherapy-induced alterations in miRNA expression and their prognostic implications in ovarian cancer.Frontiers in oncology · 2025Article
- Biomarker potential of competing endogenous RNA networks in Polycystic Ovary Syndrome (PCOS).Non-coding RNA research · 2024Review
- Chemokine Ligand 2 Promotes Migration in Osteosarcoma by Regulating the miR-3659/MMP-3 Axis.Biomedicines · 2023Article
- Review
- The role of MiRNA-433 in malignant tumors of digestive tract as tumor suppressor.Cancer reports (Hoboken, N.J.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) are a class of short non-coding RNAs with a length of approximate 22 nuclei acids that can be expressed both as an oncogene and tumor suppressor gene in human cancers. MiRNAs can participate in the post- transcriptional regulation of gene expression, and regulate the several cancer-related processes, including proliferation, apoptosis, metastasis, etc. RECENT
findingsExpression of miRNA-433 has been reported to vary in different tumors and affected by various factors. We have summarized the different previous studies and found that miRNA-433 can significantly inhibit the growth of the cancer cells not only in malignant tumors of the digestive tract, but also in lung cancer, breast cancer, cervical cancer, ovarian cancer, bladder cancer, renal carcinoma, glioma, retinoblastoma and osteosarcoma.
conclusionWhen the expression of miRNA-433 was up-regulated, the proliferation, metastasis and invasion abilities of the malignant tumor cells were significantly inhibited. At the same time, the potential mechanisms through which miRNA-433 can suppress the growth and metastasis of the cancer cells were found to be basically the same, and involved modulation of the specific signaling pathways or target genes in the malignant tumors. Overall, it can be concluded that miRNA-433 can serve as potential and valuable therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.